Literature DB >> 32743678

HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.

Jiahong Jiang1, Shaohai Wang1, Zehua Wang1, Jing Cai1, Lingling Han1, Lisha Xie1, Qing Han1, Wenwen Wang1, Yifan Zhang1, Xiaoqi He2, Chun Yang3.   

Abstract

PURPOSE: The HOX transcript antisense RNA (HOTAIR) has been reported to be aberrantly expressed in ovarian cancer (OC). Abnormal high expression level of HOTAIR has been found to be associated with poor overall survival of OC patients. Yet, the role of HOTAIR in paclitaxel resistance of OC is unclear. This study aims to investigate the effect, as well as the mechanism of HOTAIR in promoting paclitaxel resistance of OC.
METHODS: Ovarian cancer cell lines with down-regulated and up-regulated expression of HOTAIR were, respectively, established. The expression of HOTAIR was confirmed by qRT-PCR. The sensitivity of ovarian cancer cells to paclitaxel was detected by MTT assays, colony formation, EdU assays, flow cytometry, and in vivo experiments.
RESULTS: An increased expression level of HOTAIR was observed in ovarian cancer cell lines following treatment with paclitaxel. When the expression of HOTAIR was down-regulated, the proliferation of ovarian cancer cells was found to be inhibited, coupled with enhanced cell sensitivity to paclitaxel. Conversely, when the HOTAIR expression was up-regulated, an opposite effect was observed on the ovarian cancer cells. In addition, cell cycle arrest in G2/M phase was also shown to be accelerated upon HOTAIR suppression. Strikingly, our results also revealed that HOTAIR plays a regulatory role in the expression of checkpoint kinase 1 (CHEK1), and that the restored paclitaxel sensitivity through knockdown of HOTAIR can be weakened by CHEK1 up-regulation. Consistently, in vivo data confirmed that the therapeutic efficacy of paclitaxel can be enhanced through down-regulation of HOTAIR, and that CHEK1 is the down-stream target of HOTAIR in inducing paclitaxel resistance.
CONCLUSION: HOTAIR confers paclitaxel resistance in epithelial ovarian cancer by increasing the protein level of CHEK1.

Entities:  

Keywords:  CHEK1; Drug resistance; HOTAIR; Ovarian cancer; Paclitaxel

Mesh:

Substances:

Year:  2020        PMID: 32743678     DOI: 10.1007/s00280-020-04120-1

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  MiR-139-3p Targets CHEK1 Modulating DNA Repair and Cell Viability in Lung Squamous Carcinoma Cells.

Authors:  Xiaoyu Zheng; Yingchun Zhang; Shaojun Wu; Bin Jiang; Yongchun Liu
Journal:  Mol Biotechnol       Date:  2022-02-12       Impact factor: 2.695

2.  LncRNA HOTAIR promotes the proliferation and invasion/metastasis of breast cancer cells by targeting the miR-130a-3p/Suv39H1 axis.

Authors:  Wenxing He; Dongmei Li; Xiaofang Zhang
Journal:  Biochem Biophys Rep       Date:  2022-05-18

Review 3.  Anti-Cancer Effects of Dietary Polyphenols via ROS-Mediated Pathway with Their Modulation of MicroRNAs.

Authors:  Yasukiyo Yoshioka; Tomokazu Ohishi; Yoriyuki Nakamura; Ryuuta Fukutomi; Noriyuki Miyoshi
Journal:  Molecules       Date:  2022-06-14       Impact factor: 4.927

Review 4.  LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms.

Authors:  Eleonora A Braga; Marina V Fridman; Alexey A Moscovtsev; Elena A Filippova; Alexey A Dmitriev; Nikolay E Kushlinskii
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

Review 5.  The Role of Long Non-Coding RNAs (lncRNAs) in Female Oriented Cancers.

Authors:  Faiza Naz; Imran Tariq; Sajid Ali; Ahmed Somaida; Eduard Preis; Udo Bakowsky
Journal:  Cancers (Basel)       Date:  2021-12-03       Impact factor: 6.639

6.  In vivo detection of dysregulated choline metabolism in paclitaxel-resistant ovarian cancers with proton magnetic resonance spectroscopy.

Authors:  Jing Lu; Ying Li; Yong Ai Li; Li Wang; An Rong Zeng; Xiao Liang Ma; Jin Wei Qiang
Journal:  J Transl Med       Date:  2022-02-15       Impact factor: 5.531

Review 7.  Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications.

Authors:  Xuehao Zhou; Xiang Ao; Zhaojun Jia; Yiwen Li; Shouxiang Kuang; Chengcheng Du; Jinyu Zhang; Jianxun Wang; Ying Liu
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

Review 8.  Functions and underlying mechanisms of lncRNA HOTAIR in cancer chemotherapy resistance.

Authors:  Chunming Zhu; Xia Wang; Yuan Wang; Kefeng Wang
Journal:  Cell Death Discov       Date:  2022-09-13

Review 9.  Long noncoding RNAs as therapeutic targets to overcome chemoresistance in ovarian cancer.

Authors:  Linjiao Chen; Jie Wang; Qian Liu
Journal:  Front Cell Dev Biol       Date:  2022-08-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.